Activator protein-1 (AP-1) inhibition prevents endothelial to mesenchymal transition in diabetes-associated atherosclerosis: a translational study.

Saved in:
Bibliographic Details
Title: Activator protein-1 (AP-1) inhibition prevents endothelial to mesenchymal transition in diabetes-associated atherosclerosis: a translational study.
Authors: Khan AW; Department of diabetes, Central Clinical School of Translational Medicine, Monash University, The Alfred Centre, Level 5, 99 Commercial Road, Melbourne, VIC, 3004, Australia. Waheed.khan@monash.edu.au., Aziz M; Department of diabetes, Central Clinical School of Translational Medicine, Monash University, The Alfred Centre, Level 5, 99 Commercial Road, Melbourne, VIC, 3004, Australia., Sourris KC; Department of diabetes, Central Clinical School of Translational Medicine, Monash University, The Alfred Centre, Level 5, 99 Commercial Road, Melbourne, VIC, 3004, Australia., Cortes JP; Department of diabetes, Central Clinical School of Translational Medicine, Monash University, The Alfred Centre, Level 5, 99 Commercial Road, Melbourne, VIC, 3004, Australia., Block TJ; Department of diabetes, Central Clinical School of Translational Medicine, Monash University, The Alfred Centre, Level 5, 99 Commercial Road, Melbourne, VIC, 3004, Australia., Dai A; Department of diabetes, Central Clinical School of Translational Medicine, Monash University, The Alfred Centre, Level 5, 99 Commercial Road, Melbourne, VIC, 3004, Australia., Maxwell S; Department of diabetes, Central Clinical School of Translational Medicine, Monash University, The Alfred Centre, Level 5, 99 Commercial Road, Melbourne, VIC, 3004, Australia.; Epigenetics in Human Health and Disease Program, Baker Heart and Diabetes Institute, Melbourne, Australia., Okabe J; Department of diabetes, Central Clinical School of Translational Medicine, Monash University, The Alfred Centre, Level 5, 99 Commercial Road, Melbourne, VIC, 3004, Australia.; Epigenetics in Human Health and Disease Program, Baker Heart and Diabetes Institute, Melbourne, Australia., Pyper E; Department of diabetes, Central Clinical School of Translational Medicine, Monash University, The Alfred Centre, Level 5, 99 Commercial Road, Melbourne, VIC, 3004, Australia., Paneni F; Center for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zurich and University of Zürich, Wagistrasse 12, Schlieren, 8952, Switzerland., Cooper ME; Department of diabetes, Central Clinical School of Translational Medicine, Monash University, The Alfred Centre, Level 5, 99 Commercial Road, Melbourne, VIC, 3004, Australia., Jandeleit-Dahm KA; Department of diabetes, Central Clinical School of Translational Medicine, Monash University, The Alfred Centre, Level 5, 99 Commercial Road, Melbourne, VIC, 3004, Australia.; Leibniz Institute for Diabetes Research, Heinrich Heine University, Dusseldorf, Germany.
Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2026 Jan 29; Vol. 25 (1), pp. 61. Date of Electronic Publication: 2026 Jan 29.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1475-2840
DOI:10.1186/s12933-025-03060-5